GNI Group Explains Acquisition Plans, Earnings Revision and F351 Disclosure Strategy

GNI Group ( (JP:2160) ) has issued an update.

GNI Group has addressed a series of investor questions to enhance transparency around its strategy and disclosure practices, notably regarding the planned acquisition of Gyre Pharmaceuticals funded by its July 2025 overseas offering. The company aims to complete the deal by the end of 2026 but stresses that timing and capital allocation may shift depending on negotiations and the relative growth potential of other projects, with shareholder value as the primary consideration.

Management also defended the timing of its revised full-year earnings forecast, explaining that late-year external changes, the material impact of subsidiary Cullgen, and year-end asset impairment testing delayed finalization until after December 31. In addition, GNI clarified its communications on F351, stating it avoids repeating previously disclosed details, and outlined general definitions around F351’s target indication and regulatory process, while emphasizing that detailed interactions with regulators remain confidential under standard pharmaceutical industry practice.

The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.

More about GNI Group

GNI Group Ltd. is a Japan-listed biopharmaceutical company on the TSE Growth market, led by President and CEO Ying Luo. The group focuses on developing and commercializing innovative therapies, including liver fibrosis treatment F351, with operations and partnerships spanning China and overseas markets.

Average Trading Volume: 1,360,748

Technical Sentiment Signal: Buy

Current Market Cap: Yen138.6B

See more insights into 2160 stock on TipRanks’ Stock Analysis page.